Patents by Inventor Olivier Clermont

Olivier Clermont has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11041147
    Abstract: The present invention relates to a bacteriophage strain capable of producing a lytic infection in the Escherichia coli ST131-025b:H4 clone. The burden of ST131-025b:H4 Escherichia coli clonal complex in human community and hospital-acquired infections is increasing worldwide, going along with a worrying and growing resistance to betalactams and fluoroquinolones. Bacteriophage LM33_P1 infects exclusively (100% specificity) 025b E. coli strains with 70% coverage on the two major antibiotic resistant pandemic clonal complexes ST131-025b:H4 and ST69-025b. The inventors evaluated the in vivo activity of bacteriophage LM33_P1 using three different extraintestinal virulence murine models and showed that it infects bacteria in several organs.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: June 22, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), UNIVERSITÉ PARIS DIDEROT—PARIS 7, UNIVERSITÉ PARIS XIII PARIS-NORD
    Inventors: Jean-Damien Ricard, Olivier Clermont, Laurent Debarbieux, Erick Denamur, Nicolas Dufour
  • Publication number: 20190119652
    Abstract: The present invention relates to a bacteriophage strain capable of producing a lytic infection in the Escherichia coli ST131-025b:H4 clone. The burden of STl31-025b:H4 Escherichia coli clonal complex in human community and hospital-acquired infections is increasing worldwide, going along with a worrying and growing resistance to betalactams and fluoroquinolones. Bacteriophage LM33_P1 infects exclusively (100% specificity) 025b E. coli strains with 70% coverage on the two major antibiotic resistant pandemic clonal complexes STI31-025b:H4 and ST69-025b. The inventors evaluated the in vivo activity of bacteriophage LM33_P1 using three different extraintestinal virulence murine models and showed that it infects bacteria in several organs.
    Type: Application
    Filed: April 12, 2017
    Publication date: April 25, 2019
    Applicants: NSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), UNIVERSITÉ PARIS DIDEROT - PARIS 7, INSTITUT PASTEUR, UNIVERSITÉ PARIS XIII PARIS-NORD
    Inventors: Jean-Damien RICARD, Olivier CLERMONT, Laurent DEBARBIEUX, Erick DENAMUR, Nicolas DUFOUR
  • Publication number: 20190120838
    Abstract: The present invention relates to methods and kits for the rapid detection of the Escherichia coli O25b-ST131 clone. The inventors have isolated a podoviridae bacteriophage (LM33_P1) infecting the E. coli strain LM33 isolated from ventilator associated pneumonia and which belongs to clone STI3I-025b. By testing different strains of E coli belonging to 129 others various distinct serotypes (including twelve O25a) the inventors found that bacteriophage LM33_P1 is able to infect exclusively O25b strains (none of non-O25b strains could be infected by LM33_P1). The inventors have determined that the specificity displayed by bacteriophage LM33_P1 to infect only 025b serotype strains is based on a very specific polypeptide (Gp17) used by LM33_P1 to attach the bacterial cell via LPS molecule. In particular, the present invention relates to a polypeptide comprising an amino acid sequence having at least 80% of identity with the amino acid sequence set forth in SEQ ID NO:1.
    Type: Application
    Filed: April 12, 2017
    Publication date: April 25, 2019
    Inventors: Jean-Damien RICARD, Nicolas DUFOUR, Erick DENAMUR, Laurent DEBARBIEUX, Olivier CLERMONT
  • Patent number: 8178340
    Abstract: The present invention relates to human specific Escherichia coli strains.
    Type: Grant
    Filed: August 13, 2008
    Date of Patent: May 15, 2012
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Olivier Clermont, Erick Denamur, Tony Le Gall, Olivier Tenaillon
  • Publication number: 20110008449
    Abstract: The present invention relates to human specific Escherichia coli strains.
    Type: Application
    Filed: August 13, 2008
    Publication date: January 13, 2011
    Inventors: Olivier Clermont, Erick Denamur, Tony Le Gall, Olivier Tenaillon
  • Publication number: 20090298713
    Abstract: The present invention relates to products which are of nature B2+ A?, isolated from E. coli, and to their biological applications, in particular their medical (therapeutic, vaccine and diagnostic) and biotechnological applications. In the present application, the expression “of nature B2+ A?” is intended to mean presence at a frequency greater than 10% among the E. coli strains of group B2 of the ECOR collection, and at a frequency of less than 10% among the strains of group A of the same collection. A phylogenic determination method which makes it possible to rapidly and easily distinguish the groups A, B1, B2 and D of the E. coli species with more than 99% precision is in particular described.
    Type: Application
    Filed: February 4, 2008
    Publication date: December 3, 2009
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (I.N.S.E.R.M), ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
    Inventors: Edouard Bingen, Stephane Bonacorsi, Olivier Clermont, Xavier Nassif, Colin Tinsley
  • Publication number: 20030148324
    Abstract: The present invention relates to products which are of nature B2+ A−, isolated from E. coli, and to their biological applications, in particular their medical (therapeutic, vaccine and diagnostic) and biotechnological applications. In the present application, the expression “of nature B2+ A−” is intended to mean presence at a frequency greater than 10% among the E. coli strains of group B2 of the ECOR collection, and at a frequency of less than 10% among the strains of group A of the same collection. A phylogenic determination method which makes it possible to rapidly and easily distinguish the groups A, B1, B2 and D of the E. coli species with more than 99% precision is in particular described.
    Type: Application
    Filed: September 10, 2002
    Publication date: August 7, 2003
    Inventors: Edouard Bingen, Stephane Bonacorsi, Olivier Clermont, Xavier Nassif, Colin Tinsley